Loading clinical trials...
Loading clinical trials...
Low Concentrations of Atropine for Controlling Myopia Progression in School Children
Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.
Age
6 - 12 years
Sex
ALL
Healthy Volunteers
No
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Start Date
August 1, 2012
Primary Completion Date
July 1, 2017
Completion Date
August 1, 2017
Last Updated
January 30, 2018
60
ACTUAL participants
Atropine
DRUG
Lead Sponsor
Chang Gung Memorial Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06692699